The Journal of Immunology, Vol 154, Issue 1 399-412, Copyright © 1995 by American Association of Immunologists

ARTICLES

A peptide-based human T cell leukemia virus type I vaccine containing T and B cell epitopes that induces high titers of neutralizing antibodies

E Baba, M Nakamura, K Ohkuma, J Kira, Y Tanaka, S Nakano and Y Niho
First Department of Internal Medicine, Faculty of Medicine, Kyushu University, Fukuoka, Japan.

We have recently identified the principal linear neutralizing B cell epitopes of human T cell leukemia virus type I (HTLV-I) on the envelope protein gp46, amino acids (aa) 187-199, by using a number of human mAbs. We therefore propose that this region would be a good candidate for a peptide-based HTLV-I vaccine. To develop a peptide-based vaccine that can induce a high titer of neutralizing Abs against HTLV-I, we first synthesized peptides of various lengths containing aa187-199. Because the addition of gp46 aa181-186 or aa200-210 to either the N- terminus or C-terminus of SP187-199 did not alter the antigenicity of the principal neutralizing determinant, we prepared two peptide-based vaccines, MAP181-203 and MAP181-210, by conjugating SP181-203 and SP181- 210 with a branched polylysine oligomer. In rabbits, X4 to X8 and X8 to X64 titers of the neutralizing Abs were induced by immunization with MAP181-203 and MAP181-210, respectively. Furthermore, high titers of neutralizing Abs (X40 to X320) were elicited in five different strains of rats by immunization with MAP181-210. We also identified the major T cell epitope on gp46 aa194-210 in various strains of rats immunized with MAP181-210. Furthermore, the peripheral T lymphocytes obtained from the majority of HTLV-I-infected patients including HTLV-I- associated myelopathy/tropical spastic paraparesis, adult T cell leukemia/lymphoma, and healthy carriers, proliferated in response to the peptides containing aa194-210. These results indicated that MAP181- 210 contains a T cell helper epitope on aa194-210 not only in rats and rabbits, but also in humans with various HLA haplotypes. It is therefore possible that MAP181-210 could become one of the candidates for a peptide-based HTLV-I vaccine for human use.

This article has been cited by other articles:

				H. Kobayashi, T. Ngato, K. Sato, N. Aoki, S. Kimura, Y. Tanaka, H. Aizawa, M. Tateno, and E. Celis In vitro Peptide Immunization of Target Tax Protein Human T-Cell Leukemia Virus Type 1-Specific CD4+ Helper T Lymphocytes. Clin. Cancer Res., June 15, 2006; 12(12): 3814 - 3822. [Abstract] [Full Text] [PDF]

				H. Kobayashi, T. Nagato, M. Yanai, K. Oikawa, K. Sato, S. Kimura, M. Tateno, R. Omiya, and E. Celis Recognition of Adult T-Cell Leukemia/Lymphoma Cells by CD4+ Helper T Lymphocytes Specific for Human T-Cell Leukemia Virus Type I Envelope Protein Clin. Cancer Res., October 15, 2004; 10(20): 7053 - 7062. [Abstract] [Full Text] [PDF]

				R. Sundaram, M. P. Lynch, S. V. Rawale, Y. Sun, M. Kazanji, and P. T. P. Kaumaya De Novo Design of Peptide Immunogens That Mimic the Coiled Coil Region of Human T-cell Leukemia Virus Type-1 Glycoprotein 21 Transmembrane Subunit for Induction of Native Protein Reactive Neutralizing Antibodies J. Biol. Chem., June 4, 2004; 279(23): 24141 - 24151. [Abstract] [Full Text] [PDF]

				S. Blanchard, T. Astier-Gin, B. Tallet, D. Moynet, D. Londos-Gagliardi, and B. Guillemain Amino Acid Changes at Positions 173 and 187 in the Human T-Cell Leukemia Virus Type 1 Surface Glycoprotein Induce Specific Neutralizing Antibodies J. Virol., November 1, 1999; 73(11): 9369 - 9376. [Abstract] [Full Text] [PDF]

				S. M. Lonning, W. Zhang, and T. C. McGuire Gag Protein Epitopes Recognized by CD4+ T-Helper Lymphocytes from Equine Infectious Anemia Virus-Infected Carrier Horses J. Virol., May 1, 1999; 73(5): 4257 - 4265. [Abstract] [Full Text]